<DOC>
	<DOCNO>NCT01958996</DOCNO>
	<brief_summary>R-CHOP doxorubicin standard first line treatment high grade non-Hodgkin 's lymphoma . In order avoid central venous system insertion reduce hospitalization time elderly patient , develop oral chemotherapy treatment : `` OROCIEP '' trial . Nineteen patient enrol 127 chemotherapy cycle available toxicity . The estimated two-years overall survival 74 % . The main haematological toxicity neutropenia . This study still ongoing confirm recommend dose oral anthracycline .</brief_summary>
	<brief_title>Phase I/II Study Escalating Doses Idarubicin Orally Given With Oral Cyclophosphamide , Etoposide , Prednisolone Intravenous Rituximab Elderly Patient With Disseminated High Grade Non Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>CD20positive diffuse large Bcell lymphoma.WHO classification ( 55 ) Written informed consent Age &gt; 65 &lt; 80 year Performance status ( ECOG ) &lt; 3 measurable disease Serology HIV negative , Hepatites B , Hepatites C negative Serology HIV positive , Hepatite B positive , Hepatite C positive Cardiac failure .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>